Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil 9) in Solid Organ Transplant Recipients and HIV-infected Patients

Trial Profile

An Open-label Phase III Study to Investigate the Safety, Tolerability and Immunogenicity of a Nine-valent Human Papillomavirus (HPV) Vaccine (Gardasil 9) in Solid Organ Transplant Recipients and HIV-infected Patients

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 05 Feb 2019

At a glance

  • Drugs Human papillomavirus vaccine recombinant nonavalent Merck (Primary)
  • Indications Human papillomavirus infections
  • Focus Pharmacodynamics
  • Most Recent Events

    • 25 Jan 2019 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
    • 25 Jan 2019 Planned primary completion date changed from 1 Mar 2019 to 1 Sep 2019.
    • 25 Jan 2019 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top